Market Cap 37.63B
Revenue (ttm) 5.15B
Net Income (ttm) 1.40B
EPS (ttm) N/A
PE Ratio 25.50
Forward PE 23.27
Profit Margin 27.22%
Debt to Equity Ratio 0.07
Volume 970,400
Avg Vol 1,037,088
Day's Range N/A - N/A
Shares Out 145.94M
Stochastic %K 64%
Beta 0.88
Analysts Sell
Price Target $289.38

Company Profile

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry,...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 858-836-5000
Address:
9001 Spectrum Center Boulevard, San Diego, United States
SuperGreenToday
SuperGreenToday Jan. 14 at 8:29 PM
$RMD Share Price: $259.43 Contract Selected: Jul 17, 2026 $260 Calls Buy Zone: $17.43 – $21.53 Target Zone: $30.17 – $36.87 Potential Upside: 63% ROI Time to Expiration: 183 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Bigsky007
Bigsky007 Jan. 13 at 8:56 PM
$EVTV $IXHL $JAZZ $LLY $RMD Well BB 23 you picked a good day for a recap. I needed a refresher course.
1 · Reply
BullButter23
BullButter23 Jan. 13 at 8:43 PM
$EVTV Still Bullish but I jumped out a little early to move my profits into $IXHL . They’ve created a first of its kind pill (IHL-42X) to treat Sleep Apnea, which affects over 1 billion people worldwide. It’s been proven to have 83% efficacy with ZERO side effects and has been FDA fast-tracked for Phase 3. IXHL cancelled 350 million warrants and announced the option to exercise a $20M buyback. IHXL has $70M in cash on hand, which is plenty to get this drug through phase 3 and they very recently accelerated vesting its board members. Marijuana was just rescheduled (III) for pharmaceutical purposes, and IXHL owns 19 related patents with 23 more pending, which makes it the largest patented medical marijuana portfolio in the world. Its stock is currently undervalued by 6X and is due for rerate. AGM is scheduled for Thursday. Lots of speculation about a merger or buyout. Potential suitors are $RMD, $LLY, $JAZZ, etc.. with RMD having the most to lose. (CPAP machine maker.) Go check em out
0 · Reply
FlexSeries
FlexSeries Jan. 13 at 1:10 PM
0 · Reply
Chapman211
Chapman211 Jan. 12 at 10:37 PM
$IXHL $RMD had a good day. Not sure what’s in store for us but it can’t come soon enough.
0 · Reply
ZacksResearch
ZacksResearch Jan. 8 at 5:19 PM
$RMD rallies 5.1% in a year, outpacing its industry! 🚀 Despite macroeconomic headwinds, Resmed's international market expansion and strong device sales are fueling growth, with AirSense 10 and 11 leading the charge. Plus, a solid balance sheet with cash far outweighing debt supports stability. Discover the full story here 👉 https://www.zacks.com/stock/news/2814031/is-this-the-right-time-to-add-resmed-stock-to-your-portfolio?cid=sm-stocktwits-2-2814031-body-28026&ADID=SYND_STOCKTWITS_TWEET_2_2814031_BODY_28026
0 · Reply
ZacksResearch
ZacksResearch Jan. 8 at 4:19 PM
Is now the moment to add $RMD — or is this a wait-and-see setup? 🤔 ResMed is seeing rising device demand, expanding international sales, and strong liquidity, but macroeconomic pressures could still weigh on future performance — a classic push-pull setup for investors. See the full risk/reward breakdown here 👉 https://www.zacks.com/stock/news/2814031/is-this-the-right-time-to-add-resmed-stock-to-your-portfolio?cid=sm-stocktwits-2-2814031-teaser-28025&ADID=SYND_STOCKTWITS_TWEET_2_2814031_TEASER_28025
0 · Reply
RyanWxm1
RyanWxm1 Jan. 8 at 1:31 PM
$IXHL $RMD 🧐
1 · Reply
Jacob6444
Jacob6444 Jan. 5 at 8:07 PM
@Gillcorsh just imagine the specific company that would stand to lose A LOT if/when this company success with their osa drug… $RMD has no interesting in this company succeeding unless they own it. They are undoubtedly shorting the shit out of this and probably other companies too. Just hold tight yall $IXHL
2 · Reply
protrdr07
protrdr07 Jan. 4 at 10:47 PM
$RMD Does anyone here think RMD buys IXHL ? Just curious what current investors think.
1 · Reply
Latest News on RMD
IDEXX Laboratories Vs ResMed: Which Stock Could Rally?

Nov 24, 2025, 2:15 PM EST - 7 weeks ago

IDEXX Laboratories Vs ResMed: Which Stock Could Rally?

IDXX


ResMed: Safe Bet For A Recession Environment

Nov 17, 2025, 5:24 PM EST - 2 months ago

ResMed: Safe Bet For A Recession Environment


ResMed Inc. (RMD) Q1 2026 Earnings Call Transcript

Oct 30, 2025, 10:16 PM EDT - 2 months ago

ResMed Inc. (RMD) Q1 2026 Earnings Call Transcript


ResMed Inc. (RMD) Q4 2025 Earnings Call Transcript

Jul 31, 2025, 9:39 PM EDT - 5 months ago

ResMed Inc. (RMD) Q4 2025 Earnings Call Transcript


Spot Outliers Like ResMed Early with Money Flows

Jul 30, 2025, 6:08 AM EDT - 6 months ago

Spot Outliers Like ResMed Early with Money Flows


Top 15 High-Growth Dividend Stocks For July 2025

Jul 1, 2025, 9:02 PM EDT - 7 months ago

Top 15 High-Growth Dividend Stocks For July 2025

APH BAC BK DKS DPZ ELV GPN


ResMed: A Sleeping Giant Hiding In Plain Sight

Jun 9, 2025, 5:38 AM EDT - 7 months ago

ResMed: A Sleeping Giant Hiding In Plain Sight


Top 15 High-Growth Dividend Stocks For June 2025

Jun 2, 2025, 10:00 AM EDT - 8 months ago

Top 15 High-Growth Dividend Stocks For June 2025

DKS DPZ GPN INTU KLAC LRCX MPWR


Resmed Acquires VirtuOx

May 1, 2025, 9:00 AM EDT - 9 months ago

Resmed Acquires VirtuOx


ResMed: Cornering The Market In Sleep Solutions

Apr 24, 2025, 5:12 AM EDT - 9 months ago

ResMed: Cornering The Market In Sleep Solutions


ResMed Inc. (RMD) Q3 2025 Earnings Call Transcript

Apr 23, 2025, 7:16 PM EDT - 9 months ago

ResMed Inc. (RMD) Q3 2025 Earnings Call Transcript


Resmed Names Salli Schwartz as Chief Investor Relations Officer

Apr 21, 2025, 5:00 PM EDT - 9 months ago

Resmed Names Salli Schwartz as Chief Investor Relations Officer


Jan De Witte joins GHO Capital as Operating Partner

Feb 11, 2025, 4:30 AM EST - 1 year ago

Jan De Witte joins GHO Capital as Operating Partner

IART


Stock Of The Day: Trading The Range In ResMed

Feb 3, 2025, 12:59 PM EST - 1 year ago

Stock Of The Day: Trading The Range In ResMed


ResMed Inc. (RMD) Q2 2025 Earnings Call Transcript

Jan 30, 2025, 9:10 PM EST - 1 year ago

ResMed Inc. (RMD) Q2 2025 Earnings Call Transcript


SuperGreenToday
SuperGreenToday Jan. 14 at 8:29 PM
$RMD Share Price: $259.43 Contract Selected: Jul 17, 2026 $260 Calls Buy Zone: $17.43 – $21.53 Target Zone: $30.17 – $36.87 Potential Upside: 63% ROI Time to Expiration: 183 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Bigsky007
Bigsky007 Jan. 13 at 8:56 PM
$EVTV $IXHL $JAZZ $LLY $RMD Well BB 23 you picked a good day for a recap. I needed a refresher course.
1 · Reply
BullButter23
BullButter23 Jan. 13 at 8:43 PM
$EVTV Still Bullish but I jumped out a little early to move my profits into $IXHL . They’ve created a first of its kind pill (IHL-42X) to treat Sleep Apnea, which affects over 1 billion people worldwide. It’s been proven to have 83% efficacy with ZERO side effects and has been FDA fast-tracked for Phase 3. IXHL cancelled 350 million warrants and announced the option to exercise a $20M buyback. IHXL has $70M in cash on hand, which is plenty to get this drug through phase 3 and they very recently accelerated vesting its board members. Marijuana was just rescheduled (III) for pharmaceutical purposes, and IXHL owns 19 related patents with 23 more pending, which makes it the largest patented medical marijuana portfolio in the world. Its stock is currently undervalued by 6X and is due for rerate. AGM is scheduled for Thursday. Lots of speculation about a merger or buyout. Potential suitors are $RMD, $LLY, $JAZZ, etc.. with RMD having the most to lose. (CPAP machine maker.) Go check em out
0 · Reply
FlexSeries
FlexSeries Jan. 13 at 1:10 PM
0 · Reply
Chapman211
Chapman211 Jan. 12 at 10:37 PM
$IXHL $RMD had a good day. Not sure what’s in store for us but it can’t come soon enough.
0 · Reply
ZacksResearch
ZacksResearch Jan. 8 at 5:19 PM
$RMD rallies 5.1% in a year, outpacing its industry! 🚀 Despite macroeconomic headwinds, Resmed's international market expansion and strong device sales are fueling growth, with AirSense 10 and 11 leading the charge. Plus, a solid balance sheet with cash far outweighing debt supports stability. Discover the full story here 👉 https://www.zacks.com/stock/news/2814031/is-this-the-right-time-to-add-resmed-stock-to-your-portfolio?cid=sm-stocktwits-2-2814031-body-28026&ADID=SYND_STOCKTWITS_TWEET_2_2814031_BODY_28026
0 · Reply
ZacksResearch
ZacksResearch Jan. 8 at 4:19 PM
Is now the moment to add $RMD — or is this a wait-and-see setup? 🤔 ResMed is seeing rising device demand, expanding international sales, and strong liquidity, but macroeconomic pressures could still weigh on future performance — a classic push-pull setup for investors. See the full risk/reward breakdown here 👉 https://www.zacks.com/stock/news/2814031/is-this-the-right-time-to-add-resmed-stock-to-your-portfolio?cid=sm-stocktwits-2-2814031-teaser-28025&ADID=SYND_STOCKTWITS_TWEET_2_2814031_TEASER_28025
0 · Reply
RyanWxm1
RyanWxm1 Jan. 8 at 1:31 PM
$IXHL $RMD 🧐
1 · Reply
Jacob6444
Jacob6444 Jan. 5 at 8:07 PM
@Gillcorsh just imagine the specific company that would stand to lose A LOT if/when this company success with their osa drug… $RMD has no interesting in this company succeeding unless they own it. They are undoubtedly shorting the shit out of this and probably other companies too. Just hold tight yall $IXHL
2 · Reply
protrdr07
protrdr07 Jan. 4 at 10:47 PM
$RMD Does anyone here think RMD buys IXHL ? Just curious what current investors think.
1 · Reply
Dirk1969
Dirk1969 Jan. 4 at 9:48 PM
$VVOS buy out $RMD ? Lol
0 · Reply
DavidBreazeale531
DavidBreazeale531 Jan. 2 at 2:59 PM
$RMD $SNDK $ASX $MT $MCHP Great finish
0 · Reply
ZacksResearch
ZacksResearch Dec. 31 at 6:00 AM
$BSX vs. $RMD — which medical device stock has the edge right now? 👀 This head-to-head breakdown puts Boston Scientific and ResMed side by side to see which one stacks up better at this moment — no fluff, just a clear comparison. Find out which stock looks stronger now 👉 https://www.zacks.com/stock/news/2810055/bsx-vs-rmd-which-medical-device-stock-is-the-stronger-play-now?cid=sm-stocktwits-2-2810055-teaser-26710&ADID=SYND_STOCKTWITS_TWEET_2_2810055_TEASER_26710
0 · Reply
ZacksResearch
ZacksResearch Dec. 30 at 1:44 PM
$BSX or $RMD — which medical device stock is the better buy? 🤔 BSX benefits from growth in cardiovascular and MedSurg segments supported by acquisitions, while RMD sees demand in mask portfolio and AI advancements, focusing on resupply and operational leverage. Notably, BSX has a Zacks Rank #2 (Buy) vs. RMD’s Rank #3 (Hold). Discover the full comparison here 👉 https://www.zacks.com/stock/news/2810055/bsx-vs-rmd-which-medical-device-stock-is-the-stronger-play-now?cid=sm-stocktwits-2-2810055-body-26722&ADID=SYND_STOCKTWITS_TWEET_2_2810055_BODY_26722
0 · Reply
ZacksResearch
ZacksResearch Dec. 30 at 12:44 PM
Why $DXCM, $RMD, and $MASI could benefit from financial incentives in 2026! 🚀 💰 Higher HSA contribution limits mean more pre-tax savings for devices like CGMs and PAPs. 🔼 Rising Medicare premiums encourage the use of tech for cost-effective chronic disease management. Discover how these stocks are positioned to benefit 👉 https://www.zacks.com/stock/news/2810011/3-stocks-likely-to-gain-from-rising-hsa-contribution-medicare-premium?cid=sm-stocktwits-2-2810011-body-26697&ADID=SYND_STOCKTWITS_TWEET_2_2810011_BODY_26697
0 · Reply
ZacksResearch
ZacksResearch Dec. 30 at 11:44 AM
💰 Policy tailwinds hitting healthcare — here’s the quiet beneficiary trade. Rising HSA contribution limits and higher Medicare premiums in 2026 could boost demand for chronic care devices, putting $DXCM, $RMD, and $MASI in a favorable spot as patients and providers spend more on long-term care needs. See how these policy shifts could play out 👉 https://www.zacks.com/stock/news/2810011/3-stocks-likely-to-gain-from-rising-hsa-contribution-medicare-premium?cid=sm-stocktwits-2-2810011-teaser-26695&ADID=SYND_STOCKTWITS_TWEET_2_2810011_TEASER_26695
0 · Reply
InLongtoRetire
InLongtoRetire Dec. 26 at 10:05 PM
0 · Reply
MicroServiceM
MicroServiceM Dec. 25 at 5:15 AM
$RMD Long‑horizon outcomes depend on management’s ability to convert scale into defensible margin expansion, with outcomes shaped by timing and discipline. Outcomes hinge on delivery, not scale.
0 · Reply
JarvisFlow
JarvisFlow Dec. 18 at 1:04 PM
Stifel updates rating for ResMed ( $RMD ) to Hold, target set at 270 → 260.
0 · Reply
JarvisFlow
JarvisFlow Dec. 16 at 11:21 AM
Baird has updated their rating for ResMed ( $RMD ) to Neutral with a price target of 275.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 16 at 9:57 AM
$RMD Current Stock Price: $253.16 Contracts to trade: $250 RMD Dec 19 2025 Call Entry: $3.91 Exit: $5.51 ROI: 41% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
skepticalbee
skepticalbee Dec. 10 at 7:35 PM
$IXHL $RMD Really? Given the intrisically intellectual nature of your post, I'm very eager to hear your logic for this prediction. Care to share?
1 · Reply